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INTRODUCTION 
Simian immunodeficiency virus (SIV) was prevalent among 
chimpanzees for several thousands of years. For unknown reasons it had 
remained silent without harming humans. During the middle of twentieth 
century, it had transformed into Human Immunodeficiency virus. Numerous 
hypotheses have been forwarded for explaining this phenomenon. In most of 
the theories, colonisation of African nations, rapid urbanisation, unprotected 
sex and travel were being attributed for the sudden transformation and spread. 
[1][2]
 After transformation it had taken only few years for the pandemic to get 
established. 
Today the virus has spread worldwide and has become a biggest public 
health challenge for low income countries. As it primarily affects working 
population of a nation, it has resulted in a great economic burden. Infections 
which were previously uncommon and sporadic, are being frequently 
reported. Several countries are witnessing resurgence of tuberculosis.  
HIV is one of the most extensively studied virus. Thousands of articles 
are being published each year about HIV/AIDS. This has led to immense 
knowledge about the virus as well as the disease. Epidemiological data, 
statistics and guidelines are regularly updated by international bodies. 
Mandatory screening with effective testing methods have effectively brought 
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down blood products related transmission to a negligible rate. Active 
campaigns about HIV have resulted in increased awareness among public. 
Global annual new HIV infection rate have started to decline. Treatment 
regimens have been changed to improve the drug compliance as well to 
minimise adverse effects. Now patients are able to lead a normal life like any 
other person with the help of effective therapeutic regimens. In developed 
nations like United States, many patients who are under treatment remain 
asymptomatic for more than two decades. 
Despite all these achievements in the field of HIV/AIDS, most of the 
studies from around the world show that greater proportion of PLHA is being 
diagnosed at very late stages. Initiation of ART in early stages has shown to 
improve the life expectancy and reduce the risk of opportunistic infections 
(OIs). In fact newer guidelines are promoting initiation of drugs at higher 
level of CD4 counts (at 500/µl).  
Diagnosing PLHA at early stages has thus become an essential step to 
utilise the maximum benefits available. CDC has recommended including 
HIV screening in routine basic blood investigations performed during a health 
visit. In conditions like papular pruritic eruptions and immune 
thrombocytopenic purpura, diagnosis of HIV must always be considered. As 
the patient becomes symptomatic after a long latent period, one of the earliest 
symptoms would be frequent upper respiratory tract infections. Clinical 
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profile of HIV/AIDS patients varies in different geographical regions. Kaposi 
sarcoma which is very common in Africa and United States has been rarely 
reported from India. Common mode of transmission also varies between 
countries and also within a nation. Homosexuals carry high risk for acquiring 
HIV in USA whereas heterosexual route is the commonest mode of 
transmission in India. Injection drug users have high risk for HIV acquisition 
in north eastern states of India.  Thus for practising physicians it becomes 
necessary to know about various presenting clinical manifestations of HIV.  
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AIM 
 
1.  To study about the clinical profile of HIV at the time of diagnosis. 
2.  To study about the mean CD4 count among newly diagnosed HIV patients. 
3. To study about the correlation between CD4 count and the various clinical  
     parameters. 
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HISTORY 
The existence of an immunodeficiency disease was first suspected in 
1981 in USA. This was after publication of several articles about cases of 
Pnuemocystis carnii pneumonia in a group of young homosexual men. 
[3]
 The 
disease was soon named as GRID- Gay related immunodeficiency disease. 
[4]
 
Later it was found to be prevalent also in non gay population. CDC later 
coined the term acquired immunodeficiency syndrome (AIDS) 
Luc Montaignier was the first to isolate HIV from lymphoid ganglions 
for which he was awarded Nobel Prize. He named it as Lymphadenopathy-
associated-virus (LAV). Later Robert Gallo proved that AIDS is infact caused 
by LAV. He named the virus as human T-cell lymphotrophic virus-3(HTV-
3). Later CDC coined the term Human immunodeficiency virus (HIV). 
Earliest documentation of HIV was from a specimen (taken on 1959) 
of a Congolese man. HIV was detected from his preserved blood sample. But 
whether he developed AIDS was not known. 
ELISA test became the first serological test for detection of HIV. 
During late 1980s Lamivudine was approved by FDA for treatment of HIV. 
Later protease inhibitors and other drugs came to the market which had 
revolutionised the management of HIV/AIDS thereby leading to drastic 
decline in morbidity and mortality as well as improvement in quality of life. 
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The staggering global epidemic has been well matched by prolific scientific 
advances in the field of HIV including virology, immunology, 
pathophysiology, diagnostics, treatment and vaccine development. 
[5]
 
EPIDEMIOLOGY: 
Globally around 34 million are affected with HIV infection. About 30 
million people died so far since the onset of this epidemic. Although HIV is 
prevalent all over the world, almost all cases are from middle and low income 
countries especially sub-Saharan  Africa. There is a declining trend in global 
epidemic with decrease in number of new cases reported as well as reduction 
in number of AIDS related death. 
Latest global statistics:
[6]
 
Total Number Of PLHA:                                     34.0 Million  
Prevalence rate(for ages between 15–49)  :                     0.8%  
People died of AIDS In 2011:                               1.7 million  
New HIV infections in 2011 :                                2.5 million 
 
According to recent statistics from National AIDS control organisation 
(NACO),
[7]
 approximately 24 lakh people are affected with HIV/AIDS in 
India. Tamil Nadu which is one of the high prevalent states for HIV now 
accounts for about 150,000 cases. In  2009 , about 172000 died because of 
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HIV in India. Now annual HIV incidence in India has been reduced 
dramatically. Recent analysis showed there is a 50% decline in new incidence 
of HIV. In 2000 the number of new infections reported were 270,000 whereas 
in 2009 it has been reduced to 120,000. 
[8] 
 
VIROLOGY: 
HIV belongs to family retroviridae and genus lentivirus. The following 
viruses comes under this family.
[8]
 
1. HTLV-1 which causes tropic spastic paraparesis and Adult T- cell 
leukemia 
2. HTLV-2 which is more common than HTLV-1 but no disease has yet 
been reported 
3. HIV-1  which causes AIDS 
4. HIV-2  which also leads to AIDS but much less common than HIV-1 
 
 
MORPHOLOGY OF HIV: 
Virion :  Spherical in shape. 
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      80–100 nm in diameter.      
      It has cylindric core.  
Envelope:  Present   
Inner nucleocapsid contains viral genome and also various enzymes 
including reverse transcriptase and integrase. Outer envelope contains many 
spikes which represents membrane glycoproteins. The envelope contains two 
important protein that  play vital role in binding of virus to host cell 
membrane. They are gp120 and transmembrane protein gp41. The outer 
membrane contains not only viral proteins but also host proteins that are 
derived during budding process. Host proteins that are commonly found are 
MHC class I and II antigens. 
       Outstanding characteristics of HIV:
[9]
 
1. Predominantly affected cells: cells involved in immune function  
2. Permanent association of provirus within the infected cells.  
3. Expression of virus: restricted in some cells in vivo. 
4. Long clinical latency: Disease progresses very slowly 
5. Replication: species-specific. 
 
 
VIRAL GENOME: 
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The viral genome has following characteristics, It is made up of 
ribonucleic acid (RNA).It has two single stranded positive sense RNA 
particles. It is 9kb in length. It codes for nine genes. The nine genes are gag, 
pol, env, tat, rev, nef, vif, vpr and vpu. In HIV-2 vpu is replaed by vpx.
[10]
 
GENETIC DIVERSITY AND CLASSIFICATION OF HIV: 
HIV is broadly divided into two types HIV-1 and HIV-2, of which 
HIV-2 is uncommon and epidemiologically less significant when compared 
to HIV-1.One of the unique characteristics of HIV-1 is its high degree of  
genetic diversity. Now to name different strains of the virus six categories are 
being used 
[11]
. 
1. GROUPS 
2. SUBTYPES 
3. SUB-SUBYPES 
4. Circulating recombinant forms 
5. Unique recombinant forms 
6. Geographically distinct lineages 
 
 
GROUPS: 
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It includes M,N,O and P.  Group M is the commonest cause of HIV 
around the globe. It has further been classified into various clades, subsubtyes 
and CRFs.  
SUBTYPES: 
Group M divided into various clades: A,B,C,D,E,F,G,H,J,K2 
SUB-SUBTYPE: 
Subtypes A and F are divided further into A1, A2, F1 and F2. Subtypes 
B and D does not show much genetic variation from each other and in fact 
should be included in sub-subtypes, but they are retained in subtypes itself in 
order to avoid confusion. 
CIRCULATING RECOMBINANT FORM (CRF) : 
These are hybrid strains formed in an individual who has dual infection 
with two different strains. 
 
 
 
 
 
GEOGRAPHIC DISTRIBUTION OF VARIOUS HIV STRAINS [12]  
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1. Sub-Saharan Africa Subtype C (most common) 
Subtype B and G,    CRFO2_AG 
2. India Subtype C 
3. China Subtypes B, C and  
BC recombinant forms 
3. Southeast Asia CRF01_AE 
4. North America and some 
parts of South America 
Subtype B 
5. Australia Subtype B 
6. Western Europe Subtype B 
7. Eastern Europe  Subtype A,B and  
AB recombinant forms 
 
New emerging strains:[13] 
Thai B.   Indian C. southern China* 
CRF03_AB  Former soviet union 
CRF14_BG  Spain*   Portugal*  
BF recombinant forms South America  
CRF35_AD  Afghanistan and Iran* 
*predominantly among injection drug users 
INITIAL PATHOGENESIS: 
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 HIV enters through a breach in the mucous membrane. It binds to 
resting CD4 cells in lamina propria. It also binds to the surface of dendritic 
cells through specialised C-type lectin receptors called  DC-SIGN.
[14] 
Success 
rate of sexual route transmission is very low because of sparsely distributed 
CD4 cells in lamina propria. The dendritic cells are then carried to draining 
lymph nodes where it facilitates binding of virus to CD4-T Lymphocytes. 
CD4 cells may exist in two forms 
[15]
. 1) Resting state. 2) Activated state. 
CD4 cells are polyclonal group of cells which are usually quiescent and when 
body is exposed to microorganisms, individual clones are activated in 
response to specific antigenic stimuli. So during infectious states, activated 
CD4 cells are increases. In HIV there is also a non specific activation of all 
clones of CD4 cells. 
Activated CD4 cells are characterised by high rate of DNA replication, 
transcription and translational process. If HIV is integrated into genome of 
such cells, it also undergoes high degree of replication. 
 
 
 
PROTEINS THAT PLAY VITAL ROLE IN INITIAL 
PATHOGENESIS 
[16] 
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Gp120 CD4 receptor ligand. Appears  like numerous spikes over 
the envelope of  the virion  
Gp 41 Transmembrane protein in the virion. Penetrates host 
membrane and coil upon itself thereby helping in fusion  
CD4 Surface protein over T lymphocytes 
CCR5 A beta chemokine receptor over host cells like lymphocytes 
, dendritic cells, macrophages and glial cells 
CXCR4 Predominat coreceptor used by HIV  during late stages of 
infection 
 
FUSION: 
 Gp120 present over the virion gets attached to CD4 molecule which is 
found predominantly in T helper cells. The protein undergoes conformational 
change. This leads to exposure of underlying protein Gp41. This is present 
beneath Gp120. It also results in binding of host cell through co-receptors 
CCR4/CXCR5. Gp41 penetrates the host membrane, thereby bringing 
together viral and cellular  membrane resulting in fusion.  
FOUNDER VIRUS: 
Not all viruses of infected individual has ability to transmit disease. It 
is to be noted that once infection is disseminated and established the virus 
 20 
during its replication in various lymphoid tissues acquires extreme genetic 
diversity. So there is a high degree of variation in genetic characteristics and 
immunological response of existing virus in the plasma and the initial founder 
virus 
[17]
      
CHARACTERISTICS OF FOUNDER VIRUS 
1. Short V1-V2 loop 
2. Minimal N-linked Glycosylation 
3. Underrepresentation in the plasma viremia of TP* 
4. Limited genetic diversity 
5. Rapid divergence after transmission 
6. Presence of effective neutralizing antibodies in TP* 
*TP-Transmitting partner 
The virus after infecting CD4 cells of draining lymphoid organ (in case 
of blood borne transmission spleen is the initial organ affected). Later it gets 
disseminated into other lymphoid organs. One of the primary target for he 
virus is Gut Associated Lymphoid Tissue (GALT). GALT is rich in CD4 
cells. Infection and depletion of all CD4 cells in GALT indicates that 
infection has been widely disseminated and firmly established. 
IMMUNE SYSTEM EVASION OF HIV 
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 Despite the most effective and  potent immune mechanism s possessed  
by human beings , Human Immunodeficiency virus escapes all the defence 
mechanisms and continue to survive within the host, thereby creating a great 
challenge to the scientific world to eradicate the virus from the infected 
individual. 
 Some of the mechanism by which the virus evades immune system are 
mentioned below. 
[18]
 
1. Presence of latently infected cells acts as a reservoir of infection. 
These cells remain dormant until activated 
2. HIV is extremely recombinogenic. The rapid burst of viral 
replication results in extreme degrees of genetic variation within the viral 
population. So antibodies produced by immune system may not be effective 
in neutralizing the virus because of rapid selection process by the virus. 
3. CD4 Helper cells play a central role in antigen driven specific 
immune response to a foreign antigen. Antigen presenting cells present 
foreign antigen to CD4 cells through MHC molecule. This activates the 
antigen specific clones of CD4 cells. These activated cells promote 
production of antibodies and stimulate cytotoxic T lymphocytes. As 
mentioned earlier, HIV actually infects and depletes CD4 cells resulting in 
immunocompromised state 
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4. HIV can transfer from one cell to another through virological 
synapses. This protects the virus from exposure to immune mechanisms 
5. For infected cells to be recognised and eliminated by CD8 cells, 
infected cells should express MHC molecule over its surface. But in HIV 
infected cells these molecules are poorly expressed because of 
underrepresentation. 
Mechanism of immune evasion by Gp120 from neutralizing antibody 
1. Conformational masking of antigenic epitopes 
2. High degree of glycosylation of the protein  
3. Presence of  hypervariable regions 
 
 
 
 
PROTEINS WITH ANTIVIRAL ACTIVITIES IN  HUMAN CELLS: 
1. APOBEC3G 
2. TRIM5α 
3. TETHERIN 
 23 
APOBEC3G: 
 It causes suppression of viral transcription. 
[19] 
It acts on viral genome 
and substitute adenosine in the place of guanine in the viral genome. The 
virus can easily overcome its action by ubiquitinisation and degradration of 
the protein. This is carried out by vif gene. 
TRIM5α: 
 This protein causes premature uncoating of viral nucleocapsid in 
cellular cytoplasm itself.
[20] 
Virus evades this cellular antiviral mechanism by 
producing variation in capsid protein 
TETHERIN: 
 This is a newly found molecule present in the host cytoplasm.
[21]
 It is 
otherwise called CD317. It inhibits budding of newly formed virus through 
cellular membrane. Viruses are sequestered in tetherin mediated vesicles. 
Action of tetherin is inhibited by increased production of vpu protein by the 
virus 
MODE OF TRANSMISSION 
Common modes of transmission of HIV are 
1. SEXUAL ROUTE 
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2 .BLOOD AND BLOOD PRODUCTS 
3. MOTHER TO CHILD TRANSMISSION 
4, INJECTION DRUG ABUSE 
5. TRANSMISSION TO HEALTH PERSONNELS  
 
SEXUAL TRANSMISSION: 
This is the commonest mode of transmission of HIV around the globe 
although this is much less efficacious method than other routes. Among all 
high risk groups, MSM (men having sex with men) carry highest risk of 
acquiring the infection. Historically HIV was named GRID i.e., Gay Related 
Immunodeficiency and was believed to be an immunosuppressive disease of 
male homosexuals. 
         Females carry higher risk of acquisition of virus during a vaginal 
intercourse than males. This is because of relatively longer duration of 
exposure of female genital tract to infected seminal fluid. 
 
Risk factors for HIV transmission 
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1. High viral load in transmitting partner 
2. Multiple sex partners 
3. Serodiscordant partners 
4. Unprotected sex 
5. Uncircumcised individuals 
6. Presence of sexually transmitted diseases 
7. Anal intercourse 
 
In the presence of sexually transmitted diseases, genital ulcerations 
provide the necessary mucosal breach for entry of HIV. So the risk of HIV 
transmission is high in the presence of STDs. In addition, STDs and also 
urinary tract infections can cause infiltration of genital tracts (which usually 
are sparsely distributed with inflammatory cells in the absence of STDs) with 
various inflammatory mediators including T lymphocytes thereby facilitating 
entry of virus into host cells. 
Circumcision has been shown to decrease the risk of transmission. 
Circumcision in a HIV patient has been shown to reduce the risk of 
transmission to serodiscordant spouse. 
[22]
 
 
Factors responsible for high risk in circumcised individuals 
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1. Absence of protective keratin in inner layer of foreskin 
2. Foreskin is rich in dendritic cells (antigen presenting cells) which are 
carriers of the virus 
3. High incidence of STDs in uncircumcised  individual 
4. High susceptibility of microtrauma to foreskin during sex  
 
           Plasma viral load is directly proportional to risk of transmission. 
Reducing plasma viremia using antiretroviral therapy (ART) has been shown 
to reduce the risk of transmission. Presence of high quantity of HIV RNA in 
genital tract has been shown to increase the risk of transmission. 
           Use of oral contraceptive pills (OCPs) has also been shown to increase 
the risk of HIV transmission. OCPs alter the characteristics of cervical 
mucosa thereby increasing the risk of viral entry. 
[23]
 
TRANSMISSION BY BLOOD AND BLOOD PRODUCTS: 
             The first case of blood borne transmission of HIV happened in 1978 
in a haemophiliac patient.
[24]
  Since then it became the most dreaded and 
inevitable disease among haemophiliacs for almost a decade. There was a 
gradual decline in incidence of HIV among haemophiliacs following the 
discovery of serological assays and mandatory screening of all blood products 
before transfusion. 
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             Despite the effective screening measures for all the blood products, 
still there is a minimal residual risk for transmission. Although the 
transmission rate has been brought down drastically it has never been brought 
to zero. Despite the major advances that had been achieved in science in so 
far, techniques are still lacking to detect HIV during the initial period of 
infection (window period) 
             Before the introduction of nucleic acid assays (NAT), the window 
period was more than a month. Now it has been reduced to less than two 
weeks. This risk can also be eliminated by eliciting a detailed history from the 
donors. Health personnel must ask all donors about symptoms suggestive of 
acute HIV seroconversion. Donors must be asked about their recent sexual 
activities.  
             In some countries (like the United States and France) where MSM is 
one of the common mode of transmission, male homosexuals are prohibited 
from donating blood. This has led to marked decline in blood borne HIV 
transmission. 
[48]
  
 
 
TRANSMISSION BY ORGAN TRANSPLANTATION: 
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             HIV transmission has been reported in all types of solid organ 
transplantation.
[26]  
Organ donation by HIV patients has been prohibited 
worldwide. There is growing debate to lift his ban thereby allowing HIV 
patients to donate organ HIV positive individuals who are in need of 
transplant. This will increase the availability of organs for transplantation. 
            Methods to reduce transplantation related transmission
[26]
 
1.  Excluding high risk donors 
2.  Processing of organs before transplantation to inactivate the virus 
3.  Repeating serological tests after two weeks to exclude seroconversion 
MOTHER TO CHILD TRANSMISSION:  
  Factors increasing the risk of transmission: 
1. High plasma viral load 
2. Low maternal CD4 count 
3. Prolonged duration of labor 
4. Premature rupture of membranes 
5. Chorioamnionitis 
6. Procedures facilitating spontaneous delivery 
               Perinatal period carries highest risk of transmission which is 
followed by antenatal and postnatal period. Breast feeding has been 
recommended in developing countries in all HIV positive mothers under the 
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cover of antiretroviral therapy. Antiretroviral therapy has been recommended 
in all pregnant women with HIV irrespective of viral load and CD4 count.  
 Factors that reduce risk of transmission:
[26]
 
1. Antenatal screening of all mothers during her first visit 
2. Prenatal counselling for HIV positive couples 
3. Initiation of ART during pregnancy 
4. Caesarean delivery 
CLINICAL FEATURES: 
            HIV produces a spectrum of clinical manifestations ranging from 
asymptomatic state to severe AIDS wasting syndrome. Patient may either 
present with opportunistic infections or manifestation due to the virus per se 
like HIV encephalopathy. 
ACUTE HIV SYNDROME:
[27]  
  It develops after three to six weeks of infection in more than half of 
the affected individuals. The symptoms are mostly self limiting and last only 
for few weeks. Because of acute reduction in CD4 counts, even OIs have 
been reported. In IDUs symptoms like fever, sore throat, exanthems, malaise 
are uncommon.
[28]
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           Approximately one in ten infected individual will progress to 
fulminant disease. Sometimes patient deteriorate after recovering from acute 
illness. 
Clinical manifestation during acute infection 
Systemic symptoms: 
Fever Pharyngitis 
Myalgia Arthralgia 
Weight loss Nausea 
Vomiting Diarrhea 
Headache Retroorbital pain 
Lymphadenopathy  
 
Cutaneous manifestations 
Mucocutaneous ulcers Erythematous maculopapular rash 
Neurological manifestations: 
Encephalitis Aseptic meningitis 
Acute transverse myelitis Peripheral neuropathy  
Acute demyeliniating 
Encephalomyelitis 
[29]
 
 
 
ASYMPTOMATIC STAGE: 
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             After initial state of plasma viremia and acute HIV syndrome, 
symptoms of the patient disappear and there is acute recovery of immune 
function. During initial stages there may be increase in the count of total CD8 
cells.
[30]
 
            In this stage there is a steady decline in CD4 count. The count 
decreases by 50 per year. Patient may be clinical latent even for a decade. But 
it does not mean microbiological or immunological latency. There is a 
continual destruction of immune system as well as progressive increase in 
viral load as time advances even during asymptomatic state. 
LONG TERM SURVIVORS: 
           Some patients will remain asymptomatic even after very long time. 
There are four such groups. 
1. LONG TERM NON PROGRESSORS (LTNPs): 
         They are characterised by following features 
[31]
 
Very low plasma viral load. 
Normal CD4 count. 
Prolonged asymptomatic period that may last for more than two decades. 
Not on ARTs 
2. ELITE CONTROLLERS: 
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       These are special group of LTNPs. They are characterised by
[32]
 
Extremely low plasma viral load. 
Normal CD4 count 
Strong immune response to virus 
Overrepresentation of HLA class I molecules. 
 
3. Patients on ART: 
          Antiretroviral therapy had made an immense advance in this century. 
Newer drugs and regimes have enabled the patients to live a longer and 
healthier life. These groups can be called as long-term-non-survivors. But 
they cannot be termed as LTNPs. 
4.      Fourth group includes patients who are asymptomatic despite the 
declining immune status. Unlike in the above three groups where CD4 is 
normal here it continues to decrease. These groups suddenly manifest with 
opportunistic infections 
SYMPTOMATIC STAGE: 
        There are two different international classification system for staging 
clinical presentations of HIV /AIDS.  One is by CDC (Centre for disease 
control). It classifies the disease into three stages. In India, NACO follows 
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WHO staging. It classifies the disease into four stages. The fourth stage 
includes all AIDS defining illnesses. 
Stage 1:  
Asymptomatic patients. 
Persistent generalised lymphadenopathy. 
Stage 2: 
Moderate unexplained weight loss. 
Mucocutaneous  manifestations: 
1. Papular pruritic eruptions. 
2. Seborrheic dermatitis. 
3. Angular cheilitis. 
4. Herpes zoster. 
5. Onychomycosis. 
6. Recurrent oral ulcers. 
Recurrent Respiratory tract infections: 
1. Sinusitis. 
2. Bronchitis. 
3. Otitis media. 
4. Pharyngitis. 
STAGE 3: 
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1. Severe weight loss. 
2. Unexplained chronic diarrhea 
3. Unexplained persistent fever 
4. Oral candidiasis 
5. Oral hairy leukoplakia 
6. Pulmonary tuberculosis 
7. Severe bacterial infections 
8. Unexplained anemia 
9. Unexplained thrombocytopenia 
 
STAGE 4: 
1.     HIV wasting syndrome 
2.     Pnuemocystis pneumonia 
3.     Recurrent severe or radiological bacterial 
pneumonia  
4.     Chronic herpes simplex infection 
5.     Esophageal candidiasis 
6.     Extrapulmonary tuberculosis 
7.     Kaposi sarcoma 
8.     CNS toxoplasmosis 
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9.     HIV encephalopathy 
             
            Stage 4 Conditions which require confirmatory tests 
1. Extrapulmonary cryptococcosis 
2. Disseminated non tuberculous mycobacteria 
3. Visceral leishmaniasis 
4. Crytosporidiasis 
5. Isosporiasis 
6. Invasive cervical carcinoma 
7 Candida of trachea, bronchi and lung 
8. CMV infection 
9. Lymphoma 
10. Recurrent non typhoidal salmonella sepsis 
11. Progressive multifocal leukoencephalopathy 
12. Any disseminated mycosis 
 
 
 
Diseases of respiratory system:
[34]
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1. Sinusitis: 
 It is usually caused by bacterial agents. 
 It may involve any sinuses. Patients respond very well to 
antibiotics. 
 Rarely mucormycosis may be the cause. It can cause invasive 
sinusitis. 
 In such cases, amphotericin-B and emergency debridement are 
indicated. 
2. Pneumonia: 
           It is one of the commonest complications of HIV. It occurs early 
during the course of infection. Dysfunction of neutrophils and plasma cells 
are common in HIV patients. So there is a high susceptibility to capsulated 
organisms 
  Common agents causing pneumonia: 
  Bacterial: 
1. Streptococcus pneumonia. 
2. Hemophilus influenza. 
3. Staphylococcus aureus. 
4. Pseudomonas aeruginosa. 
 Fungal :       
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1. Pneumocystis jiroveci. 
2. Other fungal agents: Rhodococcus, Coccidiodes, Histoplasmosis 
Pneumococcal vaccine has been recommended in all individuals 
despite the immune status. In all other individuals the dose must be repeated 
every five years. 
PNEUMOCYSTIS CARNII PNEUMONIA:
[35]
 
                   It is the commonest case of pneumonia among PLHA in the 
United States. In about half of these cases individuals were not aware that 
they are HIV positive. In most of the cases, CD4 count is less than 200.  
Clinical features: 
 Fever. 
 Non productive cough. 
 Dyspnea. 
 Unexplained weight loss. 
Lab features: 
 Chest x ray: Normal/ Bilateral interstitial infiltrates. 
        Rarely pleural effusion. 
 CT thorax:   It may show ground glass opacities. 
 ABG:  Hypoxia and acidosis can occur in severe cases. 
 Demonstration of organisms:  
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1.  Special staining of sputum/ bronchoalveolar lavage (eg.  
Methenamine silver stain) 
2.  Immunofluoresence staining of specimens with                                                               
monoclonal antibodies. 
                   3.     PCR for DNA amplification. 
Extrapulmonary manifestations: 
            These are common in patients on aerosolised pentamidine therapy. 
Some of the common extrapulmonary involvement are mentioned below 
 Ear: Polypoidal mass in the outer ear. 
 Eye: choroidal lesions. 
 Skin : necrotising vasulitis. 
 Bone marrow hypoplasia. 
 Intestinal obstruction. 
 Cystic or healed calcified lesions in liver, spleen, kidney, heart and 
pericardium. 
Treatment: 
          Trimethoprim-sulphamethaxazole is the treatment of choice.. Other 
alternative drugs that can be used are mentioned below. 
1. Trimethoprim+Dapsone. 
2. Atovaquone. 
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3. Clindamycin+Primaquine. 
4. Pentamidine. 
5. Trimetrexate+Leucovorin. 
 Patients should be treated for 3 weeks. Corticosteroids are 
indicated in severe disease. Steroids if used must be initiated as early as 
possible. Presence of PCP is an indication for initiation of antiretroviral 
therapy. 
Prophylaxis: 
  Co-trimoxazole is the agent of choice for both primary and 
secondary prophylaxis. Other agents that can be used are mentioned below. 
1. Once a day dapsone. 
2. Weekly therapy with Dapsone+Pyrimethamine+Leucovorin. 
3. Once a day Atavoquone. 
4. Once a month Pentamidine nebuliser therapy. 
 
 
 
TUBERCULOSIS: 
 Tuberculosis has become one of the greatest public health 
challenge around the world, especially in developing countries. Developed 
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nations are witnessing a resurgence of tuberculosis following HIV pandemic. 
It is responsible for approximately 33% of deaths among AIDS population. 
PLHA have about hundred fold increased risk for acquiring the disease when 
compared to normal population. 
Immune activation by Mycobacterium tuberculosis(MTB): 
 As previously mentioned HIV replicates only in activated 
immune cells. Mycobacterium tuberculosis by producing IFN and various 
other cytokines activate immune system. Latent viruses also are activated and 
undergo active replication thereby resulting in increased viral load. During 
the process of replication and active production of virions, lymphocytes are 
destroyed thereby causing reduction in CD4 cells. Thus tuberculosis co-
infection can accelerate the course of HIV infection. 
[36] 
Clinical and radiological features: 
  There is a wide spectrum of manifestations. Symptoms and signs 
vary according to CD4 count. 
[37] 
 
CD4 count Features Remarks 
High CD4 count Apical 
tuberculosis 
Weight loss, night sweats, fever, 
cough common 
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Low CD4 count Disseminated 
disease 
Diffuse lower lobe disease. 
Bilateral reticulonodular 
opacities. 
Pleural effusion. 
Bilateral hilar adenopathy. 
Sputum may be negative for 
AFB. 
Low CD4 count Extrapulmonary 
tuberculosis 
Meningitis. 
Tuberculous lymph node. 
Osteomyelitis. 
Abdominal tuberculosis. 
 
  Sometimes patients may even be asymptomatic. So all PLHA 
must be screened during initial evaluation. In endemic countries like India, all 
PLHA must be screened annually. 
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INVESTIGATIONS: 
1. Sputum AFB staining: negative results do not rule out PT. 
2. Sputum culture for MTB. 
3. PPD (purified protein derivative) test. 
4. Blood culture : in cases of disseminated tuberculosis. 
5. Chest X ray: varied presentation as discussed earlier. 
6. Drug susceptibility testing: to rule out drug resistant strains. 
 
  Initiation of ART must be done either after ruling out 
tuberculosis or after initiation of antituberculous agents. Otherwise it may 
lead to IRIS (Immune reconstitution Inflammatory syndrome). 
TREATMENT: 
  ATT is started just like any other patients. Rifampin is an 
inducer of CYP450. Some of the protease inhibitors and NNRTIs are also 
metabolised through the same pathway. So rifamfin should be avoided. 
Rifabutin is preferred. ART must never be started before starting treatment 
for tuberculosis 
PREVENTION: 
         WHO has recommended several preventive measures. 
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ATYPICAL MYCOBACTERIAL INFECTION: 
Common agents: 
1. Mycobacterium avium. 
2. Mycobacterium intracellulare. 
Clinical features: 
1. Fever     4.Diarrhea  
2. Weight loss            5. Lymphadenopathy 
3. Abdominal pain  
Lab features: 
1. Chest x ray: bilateral lower lobe infiltrates. 
2. Positive blood culture. 
3. Reduced haemoglobin. 
4. Raised alkaline phosphatase. 
Treatment: 
 Clarithromycin plus ethambutol combination is preferred. In 
addition rifabutin/ciprofloxacin/amikacin can be added. 
The three ‗I‘s recommended by WHO[38] 
1. Intensified case finding 
2. Isoniazid preventive therapy 
3. Infection control 
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Prophylaxis: 
      When CD4 <50/µl. 
      Drugs preferred: Azithromycin 1200 mg/ week. 
                Clarithromycin 500 mg bd. 
OTHER RESPIRATORY DISEASES 
 Idiopathic interstitial pneumonia: 
1. Lymphoid interstitial pneumonitis. 
2. Nonspecific interstitial pneumonitis. 
 Neoplastic disease: 
1. Kaposi sarcoma. 
2. Lymphoma. 
GASTROINTESTINAL MANIFESTATIONS:
[39]
 
DISEASES OF ORAL CAVITY: 
1. Oral candidiasis. 
2. Oral hairy leukoplakia. 
3. Aphthous ulcers. 
4. Ulcers due to cryptococcosis and histoplasmosis. 
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Difference between oral thrush and hairy leukoplakia: 
 Oral thrush 
[40]
 Oral hairy leukoplakia 
Etiology Candida species EBV 
Common site Soft palate Lateral surface of tongue 
Appearance White cheesy exudate. 
Erythematous borders 
White frond like lesions 
Treatment Oral antifungal agents Local podophyllin  
systemic antiviral agents 
 
DISEASES OF ESOPHAGUS: 
i. Esophagitis: 
a. Candidiasis. 
b. Cytomegalovirus esophagitis: single large ulcer. 
c. Herpes simplex esophagitis: multiple small ulcers. 
ii. Kaposi sarcoma. 
iii. Lymphoma. 
iv. Idiopathic painful ulcer: responds well to thalidomide. 
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INFECTIONS OF SMALL AND LARGE INTESTINE AND THEIR 
SPECIAL FEATURES: 
Bacterial infections: 
Salmonella typhimurium: 
It commonly presents with non-specific symptoms. 
 Long term ciprofloxacin may be needed. 
Salmonella typhi: 
 Bacteraemia is frequent. 
Campylobacter jejuni: 
 Bloody diarrhea and proctitis are predominant features. 
 It responds well to erythromycin. 
 All the above three infections are common in homosexuals 
Fungal infections: 
Cryptosporidia:
[41]
 
 Their clinical spectrum ranges from self limiting diarrheal illness to 
fatal diarrhea. 
 It is confirmed by demonstrating oocysts in stool by acid fast staining. 
 Nitazoxanide is treatment of choice. 
 Prevention: Consuming uncooked shellfish must be avoided.  
 River or lake water must be purified before use. 
Isospora belli:  
 47 
 Responds well to trimethoprim-sulphamethaxazole. 
Microsporidia: 
 Enterocytozoon bieneusi is the commonest agent. 
 Demonstration of cyst: chromotroph based stains. 
 Albendazole can be tried. 
Viral infections: 
 CMV: 
  It causes colitis. 
  It is characterized by non bloody diarrhea. 
  Colonoscopy: multiple mucosal ulcers. 
  Treatment: Ganciclovir/Foscarnet. 
 Apart from various opportunistic infections, HIV itself can cause 
malabsorption syndrome called HIV/AIDS enteropathy.  
CAUSES OF RENAL FAILURE IN HIV: 
HIVAN:
[42]
 
 It was initially reported only in injection drug users. So it was first 
named as IDU nephropathy. It is the leading cause of renal failure in PLHA.  
It is highly prevalent among blacks and Hispanics. Urinalysis shows 
microalbuminuria in early stages (in severe cases gross proteinuria). 
Ultrasound shows renomegaly bilaterally. Increased cortical echoes are noted. 
Histopathology shows focal segmental glomerulosclerosis. FSGS is of 
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collapsing type. Presence of HIVAN is an indication for starting 
antiretrovirals. Steroids and ACEI have some benefit in these patients  
Drugs causing Renal failure in HIV:
[43]
 
1. Amphotericin B. 
2. Adefovir and cidofovir. 
3. Foscarnet. 
4. Pentamidine. 
5. Cotrimoxazole: it increases serum creatinine. It competes with latter for 
tubular secretion. 
6. Indinavir: can cause renal calculi. 
7. Sulfadiazine: causes acute reversible renal injury. 
For both indinavir and sulfadiazine toxicity, adequate hydration if ensured 
will reverse the renal injury. 
SYPHILIS IN HIV:
[44]
 
 The presence of syphilis and other sexually transmitted diseases will 
facilitate the entry of virus as discussed earlier. Apart from usual 
presentations of syphilis, features which are otherwise very rare, are 
frequently reported in these groups.  
Some of the special features of syphilis in HIV are mentioned below: 
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Condylomatalata: commonest presentation  in HIV. 
Lues maligna: Necrotizing vasculitis of skin.Present as ulcerative cutaneous 
lesion. 
Neurosyphilis: presentation may range from  meningitis to stroke and hard of 
hearing.  
Patients may even be asymptomatic. 
VDRL: false positives are common. 
Anti-FTA: sometimes negative due to immunodeficiency. 
Lumbar puncture: CSF analysis to rule out neurosyphilis is recommended 
in all cases of syphilis.  
DERMATOLOGICAL DISEASES IN HIV AND THEIR SPECIAL 
FEATURES:
[45]
 
Seborrheic dermatitis:  
  It is one of the common cutaneous manifestations. Sometimes 
pityrosporum are detected from the lesions. 
Folliculis: 
  It is usually seen in individuals with CD4 less than 200. 
Pruritic popular eruptions: 
  It is usually seen as multiple papularlesion. 
  Common sites are extensor surfaces, face and torso. 
Eosinophilic pustular folliculitis: 
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 It is characterised by infiltration of hair follicles with eosinophils. 
 Clinically they present with perifollicular papules and plaques. 
 Patients show elevated IgE levels.  
 Lesions are often associated with mites and hence may respond to 
topical antihelminths 
Norwegian scabies: 
 It is the most severe form of scabies. 
 Pruritis is uncommon in this form. 
 Topical agents are of little benefit. Oral ivermectin may be preferred. 
CNS DISEASE: 
Toxoplasmosis: 
 It is the most common ICSOL among PLHA. MRI usually shows 
multiple ICSOLs. Basal ganglion and peripheries of the cerebrum are the 
common site for infection. Presence of a single ICSOL is highly unlikely in 
this infection, but can rarely occur. Results of serological testing are always 
positive. Negative result rules out the disease. Diagnosis is usually made 
presumptively in a patient with MRI finding and positive serology. Trial 
therapy can be initiated. Imaging is repeated after two weeks. 
 
CNS lymphoma: 
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 It is another common ICSOL among PLHA. It is a type of non-
Hodgkins lymphoma. Clinically it presents like toxoplasmosis. Focal 
neurological deficits are common. The lesions are usually single (unlike 
toxoplasmosis where it is usually multiple). Biopsy confirms the diagnosis. 
But it should be done only in cases where ICSOL fail to resolve even after a 
trial with treatment  for toxoplasma. 
 
DIFFERENTIAL DIAGNOSIS FOR ICSOLs* IN HIV 
CONDITIONS Supportive clinical features and tests 
Toxoplasmosis MRI 
Positive serology for Toxoplasmosis. 
Primary CNS lymphoma MRI. 
Stereotactic Biopsy. 
Bacterial abscess Positive blood culture recently. 
Tuberculoma Positive tuberculin tests. 
Cryptococcomas Recent fungemia. 
Nocardiosis Injection Drug users 
 
 
 
DISEASES OF ENDOCRINE SYSTEM: 
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THYROID ABNORMALITIES:
[45]
 
It is common in 10-15% of patients. Subclinical hypothyroidism is the 
most commonly detected thyroid abnormality among these patients. 
Effects of ART on thyroid function: 
1. It may result in elevated levels of TSH. 
2. Immune reconstitution Graves can occur several months after initiation 
of therapy. 
Opportunistic infections that can cause goitre: 
1. Pneumocystis jiroveci. 
2. Cytomegalovirus. 
3. Mycobacterium. 
4. Toxoplasma. 
5. Cryptococcus neoformans. 
 
LIPODYSTROPHY:
[46]
 
 It is one of the common drug related side effects seen in PLHA. 
Lipodystrophy is characterised by following features. 
 
Hypertriglyceridemia  Hypercholesterolemia 
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Hyperglycemia Hyperinsulinemia 
Elevated apolipoprotein B  
Truncal obesity: Due to increased intraabdominal fat 
Peripheral wasting (Lipoatrophy):Noted especially in face and gluteal region 
 
The criteria for metabolic syndrome is met in about one fifth of these 
patients. Drugs to control cholesterol and triglyceride levels must be added. 
Agents of choice are atorvastatin and gemfibrozil as they have minimal drug 
interactions. 
OTHER ENDOCRINE ABNORMALITIES: 
Osteopenia. 
Osteonecrosis. 
Avascular necrosis of femur and shoulder. 
Hyponatremia due to SIADH. 
Hypogonadism. 
Adrenal insufficiency. 
 
 
 
DIAGNOSIS: 
For diagnosis of HIV infection: 
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 1. ELISA. 
 2. WESTERN BOT. 
 3. RAPID ANTIBODY TEST. 
 4. PCR 
To assess the severity of infection 
 1. CD4 count. 
 2. Estimation of viral load 
   a. RT-PCR 
   b. bDNA assay 
 
To facilitate treatment: 
 1.  drug resistance testing 
 2. HLA typing (before initiation of abacavir) 
 3. Tropism testing (before starting Maraviroc)  
 
 
 
 
 
TREATMENT:
[47]
 
PROPHYLAXIS TO PREVENT OPPORTUNISTIC INFECTIONS: 
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Pneumocystis carnii:  
 Trimethoprim-sulphamethaxazole (one double strength tablet once a 
day). 
 In all cases where CD4 < 200. 
MAC: 
 Azithromycin 1.2 g/week (recommended). 
 Clarithromycin 500 mg twice a day. 
 In all cases where CD4 is less than 100. 
Mycobacterium tuberculosis: 
         Isoniazid plus pyridoxine (300+50 mg) once a day for nine to twelve 
months. 
         Recommended for all cases with positive mantoux test (more than 
5mm). 
Toxoplasmosis  
            Cotrimoxazole similar to PCP prophylaxis.In all cases with CD4 less 
than100. 
Cytomegalovirus: 
 Ganciclovir 1000 mg trice a day. 
 In all cases where CD4 count is less than 50. 
INFECTIONS FOR WHICH IMMUNIZATIONS ARE 
RECOMMENDED IN HIV PATIENTS 
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HBV     - three doses.   
HAV     - two doses. 
Influenza    - one dose every year. 
Human papilloma virus  - recommended for age group between 
   9-26 years. 
Streptococcal pneumonia - recommended in all cases with CD4  
      more than 200. 
 
DRUGS TO PREVENT RECURRENCES/RELAPSES 
Salmonella species infection -  Ciprofloxacin 0.5g is given twice a 
day for six months. 
Herpes simplex infection  -  Valacyclovir 0.5 g is given twice a day. 
Candida    -  Fluconazole 100-200 mg once a day. 
 
 
 
ADJUNCTIVE MEDICATIONS 
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Indications for corticosteroids: 
1. Severe Pneumocystis pneumonia: beneficial only if given within 3 
days after diagnosis. 
2. IRIS.  
Epoeitin alpha: 
Dose  :  8000 units subcutaneous thrice a week. (Max 48000 
 units per week) 
Target :  haematocrit between 35 – 40% 
Indication :  PLHA with anemia with erythropoietin < 500 MU/ml 
Filgrastim and sargramostin: 
Indicated for cases of neutropenia 
ANTIRETROVIRAL THERAPY: 
 ART has made a great impact in the quality of life. Now they are able 
to lead a healthy life like normal population. But this is not without 
complications. Although cART has led to increased life expectancy in HIV 
individuals, it has also resulted in drug related health issues which were 
previously uncommon. Conditions like IRIS slowly got recognised following 
the extensive use of drugs.  
INDICATIONS FOR ART: 
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1. AIDS defining illness. 
2. Asymptomatic individuals with following conditions: 
a. CD4 count< 500 (recommendations vary according to guidelines. 
NACO recommends ART when CD4 is below 300) 
b. Rapid rate of decline of CD4(>100 per year). 
c. High plasma viremia (more than one lakh copies per microliter) 
d. Pregnancy. 
e. Post exposure prophylaxis. 
f. Patients with high risk for cardiac disease and cancers. 
g. Patients with HIV related renal impairment. 
h. Serodiscordant couple (if individual has seronegative partner). 
AIMS OF THERAPY: 
 To improve the immune status. 
 To decrease the viral load. 
 To minimise drug related adverse events. 
 To avoid drug resistance. 
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If a patient adheres to the prescribed drugs, plasma viral load should 
decline to undetectable levels in 3-6 months. If a patient defaults from the 
regimen, resistance testing must be performed before restarting ARTs. 
Factors which determine agent of choice: 
1. Past treatment history. 
2. Resistance testing. 
3. Adverse drug events. 
4. Associated conditions. 
5. Patient‘s compliance. 
6. Treatment regimens and dosage. 
NRTIs: 
1. Zidovudine 
2. Lamiudine 
3. Stavudine 
4. Didanosine 
5. Zalcitabine 
6. Emtricitabine 
7. Tenofovir 
8. Abacaviir 
 
Protease inhibitors: 
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 1. Indinavir. 
 2. Ritonavir. 
 3. Saquinavir. 
 4. Amprenavir. 
 5. Fosamprenavir. 
 6. Atazanavir. 
 7. Nelfinavir. 
 8. Tipranavir. 
 9. Darunavir. 
 10. Lopinavir/ritonavir. 
Special properties of protease inhibitors: 
 Metabolism : By liver. Through CYP450 
Drug interactions: Avoid CYP450 inducers. (rifampin) 
Advantage of ritonavir 
boosting: 
1. Decreased drug requirements. 
2. Decreased adverse events. 
Exceptions for boosting 1. Atazanavir. 
2. Nelfinavir. 
Side effects Metabolic abnormalities: 
         Hypertriglyceridemia. 
         Hypercholesterolemia. 
Lipodystrophy. 
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Monitoring: Lipid profile twice a year 
Drugs to be avoided for 
treatment of lipodystrophy: 
Simvastatin. Lovastatin. 
Agents preferred: Gemfibrozil. Atorvastatin. 
Indications for gemfibrozil: Triglyerides>500mg/dl. 
Dose:600mg(twice a day) 
 
Non necleotidde reverse transcriptase inhibitors (NNRTIs): 
  Nevirapine 
  Delavirdine.  
  Efavirenz 
  Etravirine 
  Rilpivirine 
ENTRY INHIBITORS: 
 1. Enfuvirtide.       2. Maraviroc. 
 
INTEGRASE INHIBITORS: 
1. Raltegravir  2. Eltigravir: 
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MATERIALS AND METHODS 
Design of study :  Cross sectional study 
Period of study :  July 2011 – September 2012 
Study population :  151 cases 
Ethical clearance :   Obtained 
Consent   :   Informed consent obtained 
Conflict of interest :  Nil 
Financial support :   Nil. 
Settings            :   Study was conducted in ART Centre, Government 
Rajaji Hospital. 
Selection of study subjects: 
Inclusion criteria: 
Patients who were diagnosed as HIV for the first time 
Exclusion criteria: 
 Patients who were already diagnosed as HIV positive 
 Patients who were previously on ART and discontinued 
 Children < 13 years 
Study: 
151 consecutive cases between the month of July and September were selected 
for the study after applying the inclusion and exclusion criteria as  
stated above and subjected to the following.  
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Baseline data and clinical characteristics: 
The baseline characteristics of the patients were prepared.  Age , sex, body 
weight, height, marital status, occupation, significant past history,  
smoking and drinking habits, substance abuse, history regarding sexual activities, 
history of blood transfusion and hospitalisations were noted.  
Thorough clinical examination was done in all individuals and recorded in the 
proforma. 
HIV was tested by SD BIOLINE HIV -1/2 3.0, a rapid immunochromatographic 
method and later confirmed by western blot assay.  
CD4 count was measured by BD FACScalibur flow cytometer. 
Investigations done in all patients: 
Complete hemogram including total count, differential count, 
haemoglobin, platelet count, ESR and peripheral smear. 
Renal function tests: blood urea, serum creatine 
Liver function tests: serum bilirubin, serum proteins, SGOT, SGPT, 
ALP. 
Blood sugar 
Chest x ray 
Mantoux test 
Sputum AFB 
Fundus examination: for retinopathy 
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Investigations done in selected patients: 
 Upper GI endoscopy: for esophageal candidiasis and esophagitis due to 
CMV and HSV 
 Ultrasound abdomen: for TB abdomen 
 Stool for ova and cyst 
VDRL: for syphilis 
 CT/MRI brain and CSF analysis  
ECG and Lipid profile 
Diagnosis of various opportunistic infections and other conditions were 
confirmed by concerned speciality department according to standard 
international guidelines. Patients were then classified based on modified 
WHO clinical staging of HIV/AIDS infection.  
Data were entered in Microsoft Office 2007 Excel-spread sheet. 
Analysis performed with SPSS version 17.0 statistical package. All 
continuous variables were presented as mean ± standard deviation if they 
were normally distributed. Difference in the normally distributed variables 
were assessed using t test and the pair t test for dependant variable. 
Comparison between the two individual groups was performed using t-test. 
All tests were two sided and a probability value of p<0.05 was considered 
statistically significant. 
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RESULTS 
Table – 1 
Age Distribution 
Age in years No.of cases Percentage 
< 20 3 2.0 
20 – 30 33 21.9 
31 – 40 70 46.3 
41 – 50 35 23.2 
> 50 10 6.6 
Total 151 100 
   
Mean age of the study group was 36.73 (SD±8.73). Median age was 
36. Of 151 cases 46.3% (70 cases) were aged between 31 to 40 years.  This 
was followed by age group between 41-50 years (23.2%) and 21-30 years 
(21.9%).  Out of 151 cases only three (2%) were aged below twenty years. 
6.6% were aged more than 50 years. In our study 93.4% cases were below the 
age of fifty.  
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Table – 2 
Sex Distribution 
 
Sex No. of cases Percentage 
Female 55 36.4 
Male 96 63.6 
Total 151 100 
  
Out of 151 cases , 63.1% (96 cases)were males. Only 36.4%(55 cases) 
were females   
Table – 3 
Mode of transmission 
 
Mode No.of cases Percentage 
Hetero sexual 132 87.5 
MSM* 3 2.0 
Blood transfusion 2 1.3 
Mother to child 2 1.3 
Unknown 12 7.9 
Total 151 100 
 *men having sex with men 
Heterosexual mode of transmission is responsible for 87.5% (132)of 
cases. This was followed by MSM which was responsible for 2% of cases. 
Blood transfusion related transmission is responsible for 1.3% of cases. 
Vertical transmission from mother to child is responsible for 1.3% of cases. 
In 7.9% mode of transmission was not known. 
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Table – 4 
Sex distribution  vs Spouse positive 
 
Sex Total No.of HIV 
Positive cases 
Spouse  
positive 
Female   55 46 
Male  96 41 
P value 0.019  Significant 
 
Out of 55 females , 46 of them had HIV positive partner. Out of 96 
males in our study only 41 had HIV positive partners. P value is < .019. This 
is statistically significant. 
 
Table – 5 
WHO Staging and distribution of cases 
 
Stage No.of cases Percentage 
Stage – 1 47 31.1 
Stage – 2 9 5.9 
Stage – 3 56 37.1 
Stage – 4 39 25.9 
Total 151 100 
  
37.1% of cases who were diagnosed as HIV came under WHO stage 3. 
31.1% were stage 1. Only 9 cases (5.9%) were stage 2.  25.9% of cases came 
under stage 4. 
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Table – 6 
Staging  Vs  CD4 count 
Staging CD4 count 
Mean 
SD 
1 470.28 156.53 
2 259.11 173.28 
3 204.28 111.5 
4 158.55 108.3 
 
 Stage 4 patients had the lowest mean CD4 count (158.55/µl) among all 
stages. Stage 1 had the highest mean CD4 count (470.28) when compared to 
other stages. Stage 2 had mean CD4 count of 259.11/µl and stage 3 had 
204.28/µl. 
 
Table – 7 
Staging  Vs  CD4 count 
Staging Mean CD4 
count 
SD 
Stage 4  (39) 158.5 108.3 
Other stages (112) 320.3 187.34 
p value <0.001      significant 
 
 Mean CD4 count of stage 4 was 158.5/µl which was significantly low 
with a p value of less than 0.001 when compared to mean CD4 count of other 
stages which was 320.3/µl.   
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Table – 8 
Staging  Vs  Sex distribution 
Staging Male Females 
1 20 27 
2 1 8 
3 43 13 
4 32 7 
Total 96 55 
 
      
 
Table -9 
    Staging vs sex distribution 
 Staging No of male 
cases 
No of female 
cases 
Total 
cases 
p value 
Stage 1 and 2 21      
(22%) 
35    (63.6%) 56 0.171  
(not significant) 
Stage 3 and 4 75      (78%) 20    (35.4%) 95 <0.001 
(significant) 
Total 96 55 151  
 
Of 55 females, 27 were stage 1, eight were stage 2, 13 were stage 3 and 
7 were stage 4. Of 96 male patients, 20 cases were stage 1, one cases was 
stage 2, 43 cases were stage 3 and 32 cases were stage 4. Of 55 female 
patients, 63.6%  were either asymptomatic or in stage 2. Among males 78% 
were either stage 3 or stage 4. 
 
Table – 10 
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Staging  Vs  Age 
Staging Mean age SD 
1 32.47 8.24 
2 38.22 9.03 
3 38.95 8.57 
4 38.36 7.99 
  
Mean age of patients who were Stage 1 was 32.47 whereas mean age of 
stage 3 and stage 4 were 38.95 and 38.36 respectively 
 
Table – 11 
CD4 count and distribution of patients. 
CD 4 count/µl No.of cases Percentage 
< 200 68 45.0 
200 – 300 25 16.6 
301 – 400 26 17.2 
401 – 500 9 6.0 
501 – 600 14 9.3 
600 – 700 5 3.3 
> 700 4 2.6 
Total 151 100 
    
 25 (16.6%) cases were having CD4 below 100. 45% of the cases were 
having CD4 count less than 200/µl. Only 15.2% have CD4 count of more 
than 500/µl. Twenty five cases(16.6%) have CD4 between 200 and 300. 
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Table – 12 
CD 4 count 
CD 4 count No.of cases Percentage 
< 350 107 70.9% 
> 350  44 29.1% 
Total 151 100 
P <0.001 (significant) 
 
 70.9% had CD4 count less than 350/µl  but only 29.1% had CD4 count 
more than 350/µl. This was statistically significant with a p value of less than 
0.001. 
 
Table – 13 
CD 4 count   Vs  Sex distribution 
CD 4 count Male Female No.of cases P value 
< 300 66 27 93 0.001 
Significant 
> 300  30 28 58 0.957 
Not significant 
Total 96 55 151  
 
 93 cases were having CD4 less than 300/µl , of which 66 were males 
and 27 were females. The p value is .001 which is statistically significant 
Of 58 cases who had CD4 more than 300/µl, 30 were males and 28 
were asymptomatic. The p vale is .957 which is statistically not significant. 
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Table – 14 
CD4 count   vs  Sex Distribution 
Sex CD4 count 
Mean 
SD 
Male 259.1 183.5 
Female 312.4 182.5 
P value 0.087  Not significant 
 
Overall mean CD4 count of all patients in our study were 278.5/µl (SD 
±184.37)Mean CD4 count of males were 259.1/µl. The mean CD4 count of 
females were 312.4/µl which was little higher than males.CD4 counts in 
males were not significantly lower than those of females (p value of 0.087) 
 
 
Table – 15 
Presenting manifestations in newly diagnosed HIV patients 
 No.of cases Percentage 
Asymptomatic  47 31.1 
Symptomatic 
104 68.9 
 
 
 
 
 
 
COMMON CLINICAL Percentage 
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Of the 151 cases, 104 patients are symptomatic. They have varied 
presentations. Also same patient had multiple clinical manifestations. 
The commonest presentation in our study was oral candidiasis which 
was present in 32.45% (49) of cases. This was followed by unexplained 
severe diarrhea which was present in 27.15% of cases. Unexplained severe 
weight loss (more than 10 kg) was the third most common presentation 
(23.84%). If both moderate and severe weight loss were considered together, 
CONDITIONS (no of cases) 
 
Oral Candidiasis  32.45% (49) 
Unexplained chronic Diarrhea   27.15% (41) 
Unexplained Severe Weight Loss  23.84% (36) 
Unexplained Persistent Fever  18.54% (28) 
Pulmonary Tuberculosis  17.22% (26) 
Moderate Unexplained Weight Loss  13.25% (20) 
PCP Pnuemonia  13.25% (20) 
OTHER UNCOMMON CONDITIONS: 
Lymph denopathy  7.95  (12) 
Extrapulmonary T berculosis  7.95  (12) 
Angular Cheilitis  7.28  (11) 
Oral Hairy Leucoplakia 
4.64% (7) 
Seborrheic Dermatitis 
3.97% (6) 
Herpes Zoster  3.31% (5) 
RARE CLINICAL CONDITIONS 
vere Bacterial Infections  
1 32 2
Eso hageal Candidiasis  
1.32% (2) 
Recurrent Severe Bacterial Pnuemonia  
0.66% (1) 
Cryptococcal Meningitis  
0.66% (1) 
Invasive Cervical Carcinoma  0.66% (1) 
Symptomatic Cardiomyopathy 
0.66% (1) 
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weight loss was present in more number of cases than oral candidiasis. 
Unexplained fever for more than thirty days was present in 18.58 % of cases. 
Pulmonary tuberculosis was the second most common opportunistic infection 
next only to oral candidiasis. PCP pneumonia was present in twenty cases 
(13.25%) 
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Other uncommon conditions were lymphadenopthy (7.95%), 
extrapulmonary tuberculosis (7.95%), angular cheilitis (7.28%), oral hairy 
leukoplakia (4.64 %), seborrheic dermatitis (3.97 %) and herpes zoster 
(3.31%) 
Two cases of severe bacterial infections were diagnosed to be HIV. 
One of them had pulmonary abscess and the other had submandibular 
abscess. Two patients had esophageal candidiasis. Recurrent bacterial 
pneumonia, cryptococcal meningitis, invasive cervical carcinoma and dilated 
cardiomyopathy were present in one patient each. 
 
Table – 16 
Other circumstances for HIV screening 
 
Reason for screening No.of cases 
Spouse screening* 29     (19.2) 
Voluntary screening# 12    (7.9) 
Preoperative screening* 3     (2.0) 
Child screening* 2      (1.3) 
Antenatal screening* 1       (0.7) 
Total 47       (31.1%) 
 * provider initiated clients 
# general clients from public. (client initiated clients) 
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Out of 151 cases, 47 (31%) patients were asymptomatic. 29 (19.2%) of 
them were screened because of having a HIV positive partner. Twelve 
individuals were found out to be positive after voluntary screening. Three 
cases were found out to be positive during preoperative assessment. Two 
cases of mother to child transmission were noted. One case was diagnosed 
during antenatal visit. 
Table – 17 
CD4 Count Vs  Oral candidiasis 
CD4 COUNT No.of cases Oral Candidiasis 
< 200 68 40 
> 200 83 9 
P value < 0.001  Significant 
  
Out of 151 cases 49 had oral candidiasis. 40 of them had CD4 count of 
less than 200/µl. There was significant relationship between oral candidiasis 
and CD4 count less than 200/µl, with a p value of less than 0.001. 
Table – 18 
CD4 Count Vs  Pulmonary tuberculosis 
CD4 COUNT No.of cases Pulmonary 
tuberculosis 
< 200 68 18 
> 200 83 8 
P value 0.039  Significant 
   
Out of 151 cases 26 had pulmonary tuberculosis. 18 of them had CD4 
count of less than 200/µl. There was significant relationship between 
pulmonary tuberculosis and CD4 count less than 200/µl, with a p value of 
0.039.  
Table – 19 
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CD4 Count Vs  Extra pulmonary tuberculosis 
CD4 COUNT No.of cases Extra pulmonary 
tuberculosis 
< 200 68 10 
> 200 83 2 
P value 0.024  Significant 
 
 
Table-20 
Tuberculosis involving various organs 
System Percentage (No. Of cases) 
Pulmonary tuberculosis 68.4     (26) 
Tuberculous meningitis 18.4     (7) 
Tuberculous lymph node 11        (4) 
TB abdomen 2.6       (1) 
Total no of cases 100      (38) 
 
Out of 151 cases 12 had extrapulmonary tuberculosis. 10 of them had 
CD4 count of less than 200/µl. There was significant relationship between 
extrapulmonary tuberculosis and CD4 count less than 200/µl, with a p value 
of 0.024. Tuberculous meningitis was the most common extrapulmonary 
tuberculosis followed by TB lymph node and TB abdomen. 
 
 
Table – 21 
CD4 Count Vs  PCP pneumonia 
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CD4 COUNT No.of cases PCP pneumonia 
< 200 68 17 
> 200 83 3 
P value 0.002  Significant 
  
Out of 151 cases 20 had PCP pneumonia. 17 of them had CD4 count of 
less than 200/µl. There was significant relationship between PCP pneumonia 
and CD4 count less than 200/µl, with a p value of 0.002. 
 
Table – 22 
CD4 Count Vs  Weight Loss 
 
CD4 COUNT No.of cases Weight loss 
< 200 68 42 
> 200 83 14 
P value < 0.001 significant 
 
Out of 151 HIV cases, 64 had weight loss. Among them 42 patients 
had CD4 count less than 200/µl.There was significant relationship between 
weight loss and CD4 count less than 200/µl, with a p value of less than 0.001. 
 
 
 
 
DISCUSSION 
AGE PROFILE: 
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In our study 93.4% cases were of age below fifty years and majority of 
them (46.3%) were between 31 to 40 years. This may be because of delay in 
diagnosing HIV in these patients. This was proven by the fact that mean age 
of Stage 1 was 32 years whereas for other stages it was around 38 years. In a 
study by Kumar et al
 [50]
, the mean age was thirty five years and significant 
proportion were presented with low CD4 levels (median 187/µl). Hence IEC 
and HIV/AIDS awareness campaigns should target younger age groups so 
that HIV can be diagnosed at earlier asymptomatic stage itself. 
GENDER PROFILE: 
Males (63.6%) occupy greater proportion of our study group. Also 
78% of males present in either stage 3 or 4 i.e. in advanced stages. CD4 count 
of males (259.1) were much lower than the female (312.4) counterpart but it 
was not statistically significant. But male sex had statistically significant 
association (p<0.001) with CD4 count of less than 300/µl.  Also it was noted 
that 78% of males present in either stage 3 or stage 4. 
Female sex in our study have low incidence (35.4%) for HIV. This was 
correlating with our national statistics in which HIV prevalence in females 
were thirty nine percent 
[7]
. In addition 63.6% of females were in either 
asymptomatic stage or stage 2. A study by Newmann et al 
[51]
 in South India 
showed that about 50% of newly diagnosed females were asymptomatic. It 
also showed that about eighty one percent were married and ninety percent 
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were monogamous in sex. In our study 46 out of 55 (83.6%) females were 
having HIV positive partner. In contrast only 41 out of 96 males (42.7%) 
were having HIV positive partners. There was statistically significant 
association between female sex and presence of HIV positive partner.  Our 
study indicates that male sex is predominantly responsible for transmitting the 
infection (to married women). Also it indicates the polygamous nature of 
male sex and necessity for intense awareness campaign regarding protective 
sex among the high risk male population (migrant workers, truck drivers, 
clients of sex workers) 
[7]
 
MODE OF TRANSMISSION: 
The commonest mode of transmission in our study was heterosexual 
route which is the predominant mode of transmission in India. In our study 
there were no cases reported among injection drug abusers. This may be 
because of the culture of the population studied which is predominantly from 
rural regions around Madurai. Injection drug users are uncommon in rural 
areas whereas it is quite common in urban regions. IDUs form significant 
proportion of HIV population only in north eastern states of India.
[52]
 
CLINICAL PROFILE: 
Among 151 cases, 104 were symptomatic. In our study oral candidiasis 
was the commonest opportunistic infection (32.45%) among HIV cases. This 
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was followed by pulmonary tuberculosis (17.22%). This was followed by 
PCP pneumonia.  
Besides pulmonary tuberculosis, extrapulmonary tuberculosis (7.95%) 
was also commonly seen. Tuberculous meningitis was the most common 
form of extrapulmonary tuberculosis which was followed by TB lymph node 
and TB abdomen.  
Around sixty percent of AIDS patients in India are having 
tuberculosis.
[53]
 Many Indian studies have shown that tuberculosis and 
candidiasis are the commonest OIs presenting in newly diagnosed HIV 
patients. 
[50][54]
 
High incidence of tuberculosis in newly diagnosed HIV patients is also 
due to close coordination of HIV (NACP) and TB (RNTCP) programs in 
India. All newly diagnosed HIV patients were screened for tuberculosis 
during the initial evaluation (intensified TB case finding) and vice versa i.e., 
all newly diagnosed tuberculosis are screened for HIV. In India as per 2010 
estimates, about 3.28 lakh HIV patients were diagnosed to have tuberculosis 
and twenty one thousand TB patients were found out to be HIV reactive.
[53]
 
Opportunistic infections and diseases involving oral cavity and skin 
were present in significant proportion of cases. Oral candidiasis was present 
in 32.45%, angular cheilitis in 7.28%, oral hairy leukoplakia in 4.64%, 
seborrheic dermatitis in 3.97%, herpes zoster in 3.31% of cases. As suggested 
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by Garmen et al, these manifestations can provide a potential clue to the 
underlying immunocompromised state.
[55]
 
Cryptococcol meningitis is the commonest cause of meningitis among 
PLHA. But in our study only one case was reported. This may be because of 
the fact that this infection occurs only at very low CD4 levels (<100) and in 
our study group only twenty five cases (16.6%) were having CD4 of below 
100. 
[56][[57]
  
ASYMPTOMATIC GROUP: 
31.1% cases of our study were asymptomatic. Partner screening 
contributes to 19.2% of all cases. Out of 154 cases only twelve (7.9%) were 
client initiated clients. Seropositivity rate by client driven voluntary testing is 
very low in Tamilnadu (1.69%) when compared to Manipur (7.77%).
 [7]
 
Campaigning to encourage voluntary testing is an important strategic measure 
for control of HIV/AIDS. Granich et al from Switzerland had proposed a 
mathematical model, 
[58]
 stating that implementation of universal voluntary 
testing and initiating ART can make a major impact on HIV pandemic. If 
proportion of individuals diagnosed by voluntary testing increases, it would 
definitely lead to rise in mean CD4 count and number of asymptomatic 
patients at the time of initial presentation. Early diagnosis can also prevent 
transmission to at risk serodiscordant partners. 
IMMUNOLOGICAL PROFILE: 
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In our study mean CD4 count in newly diagnosed HIV patients was 
278.5/µl. Mean CD4 count in male was 259.1/µl and in female was 312.4/µl. 
CD4 counts in males were not significantly lower than those of females (p 
value of 0.087). But 78% of males presented in either stage 3 or stage 4 (p 
value <0.001). 
 CD4 count decreases as stage advances. Mean CD4 count of stage 4 
disease was 158 which was very low (p value of less than 0.001) when 
compared to rest of the stages. Mean CD4 count of stage 1 was 470.28/µl. 
Newer treatment guidelines recommend initiation of ART at CD4 count of 
500/µl. 
[48]
 But most Indian studies show that mean CD4 count at the time of 
diagnosis were very low.
[50][54]
  
Also our study showed that there was a statistically significant 
association between low CD4 levels (<200) and risk of opportunistic 
infections like oral candidiasis (p <0.001), pulmonary (p value 0.039) and 
extrapulmonary tuberculosis (p vale 0.024) and PCP pneumonia (p <0.002). 
Risk of opportunistic infections increases with declining CD4 levels. 
LATE PRESENTERS:  
 Antinori et al has put forward definition of late presenters. 
[59]
 This has 
been implemented worldwide. The definition includes two groups. 1. Those 
with CD4 of less than 350. 2) Those presenting with AIDS defining illness. In 
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our study 70.9% presented with CD4 less than 350 and 25.9% patients 
presented with AIDS.  
Study by Michael. CG et al 
[60]
 showed that CD4 count at the time of 
initiation of ART has significant impact on immunological recovery, with 
high levels of CD4 count being associated with good response to therapy. 
Late presenters not only have poorer quality of life but they also create huge 
economic burden for the country. Financial impact due to delayed diagnosis 
has been stressed in several studies. The cost of medical care in patents 
presenting at late stages is 200% higher than those who were diagnosed 
earlier.
[61][62]
 This has been primarily attributed to frequent opportunistic 
infections and hospitalisations in the former group. 
 
 
 
SUMMARY 
 
1.  Mean age of the study group was 36.73 
2.  Males are predominantly involved. 
3.  Most of the females were married and have HIV positive partners. 
4.  Most of the males present in either stage 3 or stage 4 
5.  Heterosexual route was the predominant mode of transmission. 
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6.  Oral candidiasis and tuberculosis were the commonest opportunistic 
infections. 
7.  Weight loss, chronic diarrhea and fever of unknown origin were 
commonest non specific symptoms. 
8.  Tuberculous meningitis was the commonest extrapulmonary 
tuberculosis. 
9.  Mean age of Stage 1 was low when compared to other stages. 
10.  Mean CD4 count in our study was 278.5. For males: 259.1. For 
females: 312.4 
11.  CD4 count of stage 4 was statistically lower than other stages. 
12.  Oral candidiasis, tuberculosis and PCP pneumonia correlate 
significantly with CD4 count less than 200  
 
 
 
CONCLUSION 
 
Proportion of late presenters are very high worldwide. Early diagnosis 
in these patients would have helped them to survive for longer periods. 
Recommendations must be made to integrate HIV testing along with basic 
investigations during routine health visits in high risk individuals. Awareness 
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must be created among serodiscordant couples and HIV infected partner may 
be advised to start on ART to reduce the transmission to HIV negative 
partner. 
 
Awareness about the availability of voluntary testing must be created 
among high risk individuals as well as general population. 
The immense knowledge and scientific advances in the field of 
HIV/AIDS would become meaningless if the available valuable resources 
underutilized by the community.  So the special focus should be made to 
diagnose the HIV patients at early stages to achieve WHOs ambitious target 
of zero ―AIDS related death‖. 
 
 
 
 
ABBREVIATIONS 
HIV Human Immunodeficiency Virus 
AIDS Acquired Immunodeficiency Syndrome 
PLHA People Living With HIV and AIDS  
Cart Combined Antiretroviral Therapy 
PCP Pneumocystis carrnii Pneumonia 
NRTI Nucleoside Reverse Transcriptase Inhibitor 
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NNRTI Non-neucleoside Reverse Transcriptase Inhibitors 
OIs Opportunistic Infections 
FDA Food and Drug Administration 
CDC Centre for Disease Control 
WHO World Health Organisation 
ELISA Enzyme Linked Immunosorbent Assay 
HTLV Human T-Lymphotropic Virus 
CD4 Cluster of Differentiation 4 
MHC Major Histocompatibility Complex 
CRF Circulating Recombinant Forms 
NACO National AIDS Control Organisation 
HIVAN HIV associated Nephrropathy 
CMV Cytomegalovirus 
ICSOL Intracranial space occupying lesions 
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PROFORMA 
 
NAME    AGE/SEX: 
ADDRESS    
 
REFERRAL DEPARTMENT 
PRESENTING SYMPTOMS: 
 
PAST HX:    TREATMENT HX: 
SMOKER:Y/N ALCOHOLIC:Y/N DRUG ABUSE:Y/N 
MARITAL STATUS 
SEXUAL HABITS: 
CLINICAL FINDINGS: 
 
WEIGHT: HEIGHT:  
TC: DC:  HB:    CHEST X RAY: 
ESR:   MANTOUX:   SPUTUM AFB: 
BL. SUGAR: UREA:  CREATININE:  LFT: 
FUNDUS   VDRL: 
 
OTHER SPECIAL INVESTIGATIONS: 
 
CD4 COUNT:  
DIAGNOSIS:      SPECIALIST OPINION: 
OPPORTUNISTIC INFECTIONS: 
WHO CLINICAL STAGING: 
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